Translational research in nicotine dependence

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 3, 2013, Pages

  Turner, Jill R ^a   Gold, Allison ^a   Schnoll, Robert ^a   Blendy, Julie A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ANIMAL; BIOSYNTHESIS; GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOUSE; REVIEW; RODENT; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; TRANSLATIONAL RESEARCH;

ACETYLCHOLINE; ANIMALS; CHOLINERGIC ANTAGONISTS; CHOLINESTERASE INHIBITORS; HUMANS; MICE; NICOTINE; NICOTINIC AGONISTS; POLYMORPHISM, GENETIC; RECEPTORS, NICOTINIC; RODENTIA; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84878967048     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a012153     Document Type: Article

References (98)

1. Abreu-Villaca Y, Seidler FJ, Qiao D, Tate CA, Cousins MM, Thillai I., Slotkin TA. 2003. Short-term adolescent nicotine exposure has immediate and persistent effects on cholinergic systems: Critical periods, patterns of exposure, dose thresholds. Neuropsychopharmacology 28: 1935-1949.
2. Amen D.G., Wu JC, Taylor D, Willeumier K. 2011. Reversing brain damage in former NFL players: Implications for traumatic brain injury and substance abuse rehabilitation. J Psychoactive Drugs 43: 1-5.
3. Baker T.B., Weiss RB, Bolt D, von Niederhausern A, Fiore M.C., Dunn DM, Piper ME, Matsunami N, Smith S.S., Coon H, et al. 2009. Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. Nicotine Tob Res 11: 785-796.
4. BerrettiniW, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H, Waterworth D., Muglia P, Mooser V. 2008. α-5/α-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry 13: 368-373.
5. Besson M., David V, Suarez S, Cormier A, Cazala P, Changeux J.P., Granon S. 2006. Genetic dissociation of two behaviors associated with nicotine addiction: β-2 containing nicotinic receptors are involved in nicotine reinforcement but not in withdrawal syndrome. Psychopharmacology (Berl) 187: 189-199.
6. Bierut L.J., MaddenPAF, Breslau N, JohnsonEO, HatsukamiD, Pomerleau O.F., Swan GE, Rutter J, Bertelsen S, Fox L, et al. 2007. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 16: 24-35.
7. Breitling L.P., DahmenN, Mittelstrass K, RujescuD, Gallinat J, Fehr C., Giegling I, Lamina C, Illig T, Muller H, et al. 2009. Association of nicotinic acetylcholine receptor subunitα4 polymorphisms with nicotine dependence in 5500 Germans. Pharmacogenomics J 9: 219-224.
8. Brunzell D.H., Russell DS, Picciotto MR. 2003. In vivo nicotine treatment regulates mesocorticolimbic CREB and ERK signaling in C57Bl/6J mice. J Neurochem 84: 1431-1441.
9. Butt C.M., King NM, Hutton SR, Collins AC, Stitzel JA. 2005. Modulation of nicotine but not ethanol preference by the mouse Chrna4 A529T polymorphism. Behav Neurosci 119: 26-37.
10. Cahill K., Stead LF, Lancaster T. 2011. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 16: CD006103.
11. Caporaso N., Gu F, Chatterjee N, Sheng-Chih J, Yu K, Yeager M., Chen C, Jacobs K, Wheeler W, Landi MT, et al. 2009. Genome-wide and candidate gene association study of cigarette smoking behaviors. PLoS ONE 4: e4653.
12. Chang K.T., Berg DK. 2001. Voltage-gated channels block nicotinic regulation of CREB phosphorylation and gene expression in neurons. Neuron 32: 855-865.
13. Ciani E., Severi S, Bartesaghi R, Contestabile A. 2005. Neurochemical correlates of nicotine neurotoxicity on rat habenulo-interpeduncular cholinergic neurons. Neurotoxicology 26: 467-474.
14. Conti D.V., LeeW, Li D, Liu J, Van Den Berg D, Thomas PD, Bergen A.W., Swan GE, Tyndale RF, Benowitz NL, et al. 2008. Nicotinic acetylcholine receptor β2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 17: 2834-2848.
15. Cosgrove K.P., Batis J, Bois F, Maciejewski PK, Esterlis I, Kloczynski T., Stiklus S, Krishnan-Sarin S, O'Malley S, Perry E., et al. 2009. β2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry 66: 666-676.
16. Coutcher J.B., Cawley G, Wecker L. 1992. Dietary choline supplementation increases the density of nicotine binding sites in rat brain. J Pharmacol Exper Therapeut 262: 1128-1132.
17. Crooks PA. 1999. Chemical properties of nicotine and other tobacco-related compounds. In Analytical determination of nicotine and related compounds and their metabolites (ed. Gorrod JW, Jacob P III), pp. 69-147. Elsevier, Oxford.
18. Dajas-Bailador FA, Soliakov L, Wonnacott S. 2002. Nicotine activates the extracellular signal-regulated kinase 1/2 via the α7 nicotinic acetylcholine receptor and protein kinase A, in SH-SY5Y cells and hippocampal neurones. J Neurochem 80: 520-530.
19. De Bruin NM, Kiliaan AJ, De Wilde MC, Broersen LM. 2003. Combined uridine and choline administration improves cognitive deficits in spontaneously hypertensive rats. Neurobiol Learn Mem 80: 63-79.
20. Deuster P.A., Singh A, Coll R, Hyde DE, Becker WJ. 2002. Choline ingestion does not modify physical or cognitive performance. Mil Med 167: 1020-1025.
21. Diehl A., Nakovics H, Croissant B, Smolka MN, Batra A, Mann K. 2006. Galantamine reduces smoking in alcohol-dependent patients: A randomized, placebo-controlled trial. Int J Clin Pharmacol Ther 44: 614-622.
22. Dobelis P., Marks MJ, Whiteaker P, Balogh SA, Collins AC, Stitzel JA. 2002. A polymorphism in the mouse neuronal α4 nicotinic receptor subunit results in an alteration in receptor function. Mol Pharmacol 62: 334-342.
23. Drever B.D., Riedel G, Platt B. 2011. The cholinergic system and hippocampal plasticity. Behav Brain Res 221: 505-514.
24. Ebbert J.O., Hays JT, Hurt RD. 2010. Combination pharmacotherapy for stopping smoking:What advantages does it offer? Drugs 70: 643-650.
25. Eckenstein F., Sofroniew MV. 1983. Identification of central cholinergic neurons containing both choline acetyltransferase and acetylcholinesterase and of central neurons containing only acetylcholinesterase. J Neurosci 3: 2286-2291.
26. Fowler C.D., Arends MA, Kenny PJ. 2008. Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: Evidence from genetically modified mice. Behav Pharmacol 19: 461-484.
27. Frueh F.W., Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, Verbrugge RR, Burckart GJ, Lesko LJ. 2008. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: Prevalence of related drug use. Pharmacotherapy 28: 992-998.
28. Gahring L.C., Rogers SW. 2005. Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells. AAPS J 7: E885-E894.
29. Ghosheh O.A., Dwoskin LP, Miller DK, Crooks PA. 2001. Accumulation of nicotine and its metabolites in rat brain after intermittent or continuous peripheral administration of [2'-14C]nicotine. Drug Metab Dispos 29: 645-651.
30. Grabus S.D., Martin BR, Batman AM, Tyndale RF, Sellers E, Damaj MI. 2005. Nicotine physical dependence and tolerance in the mouse following chronic oral administration. Psychopharmacology (Berl) 178: 183-192.
31. Greenbaum L., Kanyas K, Karni O, Merbl Y, Olender T, Horowitz A., Yakir A, Lancet D, Ben-Asher E, Lerer B. 2006. Why do young women smoke? I. Direct and interactive effects of environment, psychological characteristics and nicotinic cholinergic receptor genes. Mol Psychiatry 11: 312-322.
32. Han S., Yang BZ, Kranzler HR, OslinD, Anton R, Gelernter J. 2011. Association of CHRNA4 polymorphisms with smoking behavior in two populations. Am J Med Genet B Neuropsychiatr Genet 156B: 421-429.
33. Heitjan D.F., Guo M, Ray R, Wileyto EP, Epstein LH, Lerman C. 2008. Identification of pharmacogenetic markers in smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 147B: 712-719.
34. Hendricks P.S., Ditre JW, Drobes DJ, Brandon TH. 2006. The early time course of smoking withdrawal effects. Psychopharmacology (Berl) 187: 385-396.
35. Hoft N.R., Corley RP, McQueen MB, Huizinga D, Menard S, Ehringer MA. 2009. SNPs in CHRNA6 and CHRNB3 are associated with alcohol consumption in a nationally representative sample. Genes Brain Behav 8: 631-637.
36. Holguin S., Huang Y, Liu J, Wurtman R. 2008a. Chronic administration of DHA and UMP improves the impaired memory of environmentally impoverished rats. Behav Brain Res 191: 11-16.
37. Holguin S., Martinez J, Chow C, Wurtman R. 2008b. Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. FASEB J 22: 3938-3946.
38. Hoover D.B., Muth EA, Jacobowitz DM. 1978. A mapping of the distribution of acetycholine, choline acetyltransferase and acetylcholinesterase in discrete areas of rat brain. Brain Res 153: 295-306.
39. Hu M., Liu QS, Chang KT, Berg DK. 2002. Nicotinic regulation of CREB activation in hippocampal neurons by glutamatergic and nonglutamatergic pathways. Mol Cell Neurosci 21: 616-625.
40. Hughes JR. 2007. Effects of abstinence from tobacco: Valid symptoms and time course. Nicotine Tob Res 9: 315-327.
41. Hutchison K.E., Allen DL, Filbey FM, Jepson C, Lerman C, Benowitz N.L., Stitzel J, Bryan A, McGeary J, Haughey HM. 2007. CHRNA4 and tobacco dependence: From gene regulation to treatment outcome. Arch Gen Psychiatry 64: 1078-1086.
42. Johnston M.V., McKinney M, Coyle JT. 1979. Evidence for a cholinergic projection to neocortex from neurons in basal forebrain. Proc Natl Acad Sci 76: 5392-5396.
43. Jope RS. 1979. High affinity choline transport and acetyl-CoA production in brain and their roles in the regulation of acetylcholine synthesis. Brain Res 180: 313-344.
44. Kalinichenko S.G., Okhotin VE. 2005. Unipolar brush cells-A new type of excitatory interneuron in the cerebellar cortex and cochlear nuclei of the brainstem. Neurosci Behav Physiol 35: 21-36.
45. Kelly D.L., McMahon RP, Weiner E, Boggs DL, Dickinson D, Conley R.R., Buchanan RW. 2008. Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in peoplewith schizophrenia. Schizophr Res 103: 161-168.
46. Kim H., Flanagin BA, Qin C, Macdonald RL, Stitzel JA. 2003. The mouse Chrna4 A529T polymorphism alters the ratio of high to lowaffinity α4β2 nAChRs. Neuropharmacology 45: 345-354.
47. King D.P., Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti D.V., Kaprio J, Lerman C, Park PW. 2012. Smoking cessation pharmacogenetics: Analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 37: 641-650.
48. Lawrence JJ. 2008. Cholinergic control of GABA release: Emerging parallels between neocortex and hippocampus. Trends Neurosci 31: 317-327.
49. Le Foll B, Goldberg SR. 2006. Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl) 184: 367-381.
50. Malin D.H., Lake JR, Newlin-Maultsby P, Roberts LK, Lanier J.G., Carter VA, Cunningham JS, Wilson OB. 1992. Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav 43: 779-784.
51. Marks M., Stitzel J, Collins A. 1985. Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J Pharmacol Exp Ther 235: 619-628.
52. Mehta M., Adem A, Sabbagh M. 2012. New acetylcholinesterase inhibitors for Alzheimer's disease. Int J Alzheimers Dis 2012: 728983.
53. Muir J.L., Page KJ, Sirinathsinghji DJ, RobbinsTW, Everitt BJ. 1993. Excitotoxic lesions of basal forebrain cholinergic neurons: Effects on learning, memory and attention. Behav Brain Res 57: 123-131.
54. Mukhin A.G., Kimes AS, Chefer SI, Matochik JA, Contoreggi CS, Horti AG, Vaupel DB, Pavlova O, Stein EA. 2008. Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: A PET study with 2-18FFA-85380. J Nucl Med 49: 1628-1635.
55. Munafò MR, Johnstone EC, Walther D, Uhl GR, Murphy M.F., Aveyard P. 2011. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res 13: 982-988.
56. Nides M. 2008. Update on pharmacologic options for smoking cessation treatment. Am J Med 121(Suppl 1): S20-S31.
57. Okuda T., Haga T, Kanai Y, Endou H, Ishihara T, Katsura I. 2000. Identification and characterization of the high-affinity choline transporter. Nat Neurosci 3: 120-125.
58. Oldenburg I.A., Ding JB. 2011. Cholinergic modulation of synaptic integration and dendritic excitability in the striatum. Curr Opin Neurobiol 21: 425-432.
59. Olgiati P., Bajo E, Bigelli M, De Ronchi D, Serretti A. 2012. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high-and middle-income European countries. Prog Neuropsychopharmacol Biol Psychiatry 36: 147-154.
60. Pandey S.C., Roy A, Xu T, Mittal N. 2001. Effects of protracted nicotine exposure and withdrawal on the expression and phosphorylation of the CREB gene transcription factor in rat brain. J Neurochem 77: 943-952.
61. Paul S.M., Mytelka DS, Dunwiddie CT, Persinger CC, Munos B.H., Lindborg SR, Schacht AL. 2010. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9: 203-214.
62. Perkins K.A., Donny E, Caggiula AR. 1999. Sex differences in nicotine effects and self-administration: Review of human and animal evidence. Nicotine Tob Res 1: 301-315.
63. Piasecki T.M., Fiore MC, Baker TB. 1998. Profiles in discouragement: Two studies of variability in the time course of smoking withdrawal symptoms. J Abnorm Psychol 107: 238-251.
64. Piasecki T.M., Niaura R, ShadelWG, AbramsD, Goldstein M, Fiore M.C., Baker TB. 2000. Smoking withdrawal dynamics in unaided quitters. J Abnorm Psychol 109: 74-86.
65. Picciotto M.R., Zoli M, Rimondini R, Lena C, Marubio LM, Pich E.M., Fuxe K, Changeux JP. 1998. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391: 173-177.
66. Picciotto M.R., AddyNA, Mineur YS, Brunzell DH. 2008. It is not "either/or": Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol 84: 329-342.
67. Ray R., Mitra N, Baldwin D, Guo M, Patterson F, Heitjan DF, Jepson C., Wileyto EP, Wei J, Payne T, et al. 2010. Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. Neuropsychopharmacology 35: 1374-1382.
68. Ribeiro-Carvalho A, Lima CS, Filgueiras CC, Manhaes AC, Abreu-Villaca Y. 2008. Nicotine and ethanol interact during adolescence: Effects on the central cholinergic systems. Brain Res 1232: 48-60.
69. Ribeiro-Carvalho A, Lima CS, Medeiros AH, Siqueira NR, Filgueiras C.C., Manhaes AC, Abreu-Villaca Y. 2009. Combined exposure to nicotine and ethanol in adolescent mice: Effects on the central cholinergic systems during short and long term withdrawal. Neuroscience 162: 1174-1186.
70. Saccone S.F., Hinrichs AL, SacconeNL, ChaseGA, Konvicka K, Madden P.A., Breslau N, Johnson EO, Hatsukami D, Pomerleau O., et al. 2007. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 16: 36-49.
71. Sarginson J.E., Killen JD, Lazzeroni LC, Fortmann SP, Ryan H.S., Schatzberg AF., Murphy GM Jr. 2011. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 156B: 275-284.
72. Schwartz R., Kellar K. 1983. Nicotinic cholinergic receptor binding sites in the brain: Regulation in vivo. Science 220: 214-216.
73. Shen J.X., Yakel JL. 2009. Nicotinic acetylcholine receptormediated calcium signaling in the nervous system. Acta Pharmacol Sin 30: 673-680.
74. Shimohama S., Kihara T. 2001. Nicotinic receptor-mediated protection against β-amyloid neurotoxicity. Biol Psychiatry 49: 233-239.
75. Shoaib M., Gommans J, Morley A, Stolerman IP, Grailhe R, Changeux JP. 2002. The role of nicotinic receptor β-2 subunits in nicotine discrimination and conditioned taste aversion. Neuropharmacology 42: 530-539.
76. Simon J.R., Kuhar MG. 1975. Impulse-flow regulation of high affinity choline uptake in brain cholinergic nerve terminals. Nature 255: 162-163.
77. Slotkin T.A., Bodwell BE, Ryde IT, Seidler FJ. 2008. Adolescent nicotine treatment changes the response of acetylcholine systems to subsequent nicotine administration in adulthood. Brain Res Bull 76: 152-165.
78. Soliakov L., Wonnacott S. 2001. Involvement of protein kinase C in the presynaptic nicotinic modulation of [(3)H]-dopamine release from rat striatal synaptosomes. Br J Pharmacol 132: 785-791.
79. Steiner R.C., Heath CJ, Picciotto MR. 2007. Nicotineinduced phosphorylation of ERK in mouse primary cortical neurons: Evidence for involvement of glutamatergic signaling and CaMKII. J Neurochem 103: 666-678.
80. Teather L.A., Wurtman RJ. 2005. Dietary CDP-choline supplementation prevents memory impairment caused by impoverished environmental conditions in rats. Learn Mem 12: 39-43.
81. Teather L.A., Wurtman RJ. 2006. Chronic administration of UMP ameliorates the impairment of hippocampaldependent memory in impoverished rats. J Nutr 136: 2834-2837.
82. Thorgeirsson T.E., Stefansson K. 2008. Genetics of smoking behavior and its consequences: The role of nicotinic acetylcholine receptors. Biol Psychiatry 64: 919-921.
83. Thorgeirsson T.E., Gudbjartsson DF, Surakka I, Vink JM, Amin N., Geller F, Sulem P, Rafnar T, Esko T, Walter S, et al. 2010. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 42: 448-453.
84. Totterdell S. 2006. The anatomy of co-morbid neuropsychiatric disorders based on cortico-limbic synaptic interactions. Neurotox Res 10: 65-85.
85. Walters C.L., Cleck JN, Kuo YC, Blendy JA. 2005. Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 46: 933-943.
86. Walters C.L., Brown S, Changeux JP, Martin B, Damaj MI. 2006. The β2 but not α7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice. Psychopharmacology (Berl) 184: 339-344.
87. Wang L., Albrecht MA, Wurtman RJ. 2007. Dietary supplementation with uridine-50-monophosphate (UMP), a membrane phosphatide precursor, increases acetylcholine level and release in striatum of aged rat. Brain Res 1133: 42-48.
88. Wei J., Ma JZ, Payne TJ, Cui W, Ray R, Mitra N, Lerman C, Li MD. 2010. Replication and extension of association of choline acetyltransferase with nicotine dependence in European and African American smokers. Hum Genet 127: 691-698.
89. Wessel J., McDonald SM, Hinds DA, Stokowski RP, Javitz H.S., Kennemer M, Krasnow R, Dirks W, Hardin J, Pitts S.J., et al. 2010. Resequencing of nicotinic acetylcholine receptor genes and association of common and rare variants with the Fagerstrom test for nicotine dependence. Neuropsychopharmacology 35: 2392-2402.
90. Wilking J.A., Hesterberg KG, Crouch EL, Homanics GE, Stitzel JA. 2010. Chrna4 A529 knock-in mice exhibit altered nicotine sensitivity. Pharmacogenet Genomics 20: 121-130.
91. Wilkinson D.S., Gould TJ. 2011. The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice. Behav Brain Res 223: 53-57.
92. Witten I.B., Lin SC, Brodsky M, Prakash R, Diester I, Anikeeva P., Gradinaru V, Ramakrishnan C, Deisseroth K. 2010. Cholinergic interneurons control local circuit activity and cocaine conditioning. Science 330: 1677-1681.
93. Wonnacott S., Barik J, Dickinson J, Jones IW. 2006. Nicotinic receptors modulate transmitter cross talk in the CNS: Nicotinic modulation of transmitters. J Mol Neurosci 30: 137-140.
94. Wu A.C., Fuhlbrigge AL. 2008. Economic evaluation of pharmacogenetic tests. Clin Pharmacol Ther 84: 272-274.
95. Xiao Y., Kellar KJ. 2004. The comparative pharmacology and up-regulation of rat neuronal nicotinic receptor subtype binding sites stably expressed in transfected mammalian cells. J Pharmacol Exp Ther 310: 98-107.
96. Xie P., Kranzler HR, Krauthammer M, Cosgrove KP, Oslin D., Anton RF, Farrer LA, Picciotto MR, Krystal J.H., Zhao H, et al. 2011. Rare nonsynonymous variants in α-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry 70: 528-536.
97. Zeiger J.S., Haberstick BC, Schlaepfer I, Collins AC, Corley RP, Crowley TJ, Hewitt JK, Hopfer CJ, Lessem J, McQueen MB, et al. 2008. The neuronal nicotinic receptor subunit genes (CHRNA6 and CHRNB3) are associated with subjective responses to tobacco. Hum Mol Genet 17: 724-734.
98. Zimmerman G., Soreq H. 2006. Termination and beyond: Acetylcholinesterase as a modulator of synaptic transmission. Cell Tissue Res 326: 655-669.